Perbak Capital Partners LLP Trims Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Perbak Capital Partners LLP reduced its stake in Thermo Fisher Scientific Inc. by 77.7%, selling 2,176 shares and retaining 623 shares worth around $310,000.
• CEO Marc N. Casper sold 10,000 shares of Thermo Fisher at approximately $500.96 each, representing a significant portion of his holdings.
• The company's quarterly earnings report showed earnings per share of $5.36, exceeding expectations and reflecting a revenue increase of 2.9% compared to the previous year.

Perbak Capital Partners LLP reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 77.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 623 shares of the medical research company's stock after selling 2,176 shares during the quarter. Perbak Capital Partners LLP's holdings in Thermo Fisher Scientific were worth $310,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at about $37,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock worth $13,982,763 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.6%

Thermo Fisher Scientific stock traded up $2.71 during mid-day trading on Friday, reaching $492.20. The stock had a trading volume of 1,442,575 shares, compared to its average volume of 1,624,930. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock's 50-day simple moving average is $460.72 and its 200-day simple moving average is $453.43. The firm has a market capitalization of $185.86 billion, a PE ratio of 28.47, a price-to-earnings-growth ratio of 2.61 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the firm posted $5.37 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. HSBC reiterated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.